Next Article in Journal
Rising Trend in the Prevalence of HPV-Driven Oropharyngeal Squamous Cell Carcinoma during 2000–2022 in Northeastern Italy: Implication for Using p16INK4a as a Surrogate Marker for HPV-Driven Carcinogenesis
Previous Article in Journal
The Cross Talk between Cellular Senescence and Melanoma: From Molecular Pathogenesis to Target Therapies
Previous Article in Special Issue
Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 9
10.3390/cancers15092641
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2022, 14(1), 230.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230

by
Ramya Ambur Sankaranarayanan
1,
Jennifer Peil
1,
Andreas T. J. Vogg
1,
Carsten Bolm
2,
Steven Terhorst
2,
Arno Classen
2,
Matthias Bauwens
1,3,4,
Jochen Maurer
5,
Felix Mottaghy
1,3 and
Agnieszka Morgenroth
1,*
1
Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany
2
Institute of Organic Chemistry, RWTH Aachen University, 52056 Aachen, Germany
3
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), 6229HX Maastricht, The Netherlands
4
School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, 6229HX Maastricht, The Netherlands
5
Department of Gynecology and Obstetrics, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(9), 2641; https://doi.org/10.3390/cancers15092641
Submission received: 22 March 2023 / Accepted: 3 April 2023 / Published: 6 May 2023
(This article belongs to the Special Issue Radiopharmaceuticals for Oncological Diseases)
Versions Notes
The authors wish to replace the ‘Author Contributions’ statement and the affiliation for Jochen Maurer of this article [1] with the following version since a wrong version was uploaded due to oversight:
Author Contributions: A.M. and F.M. supervised and administered the project. R.A.S., A.M. and F.M. contributed to the study conception and design. R.A.S. and J.P. analyzed and curated the data. A.T.J.V., A.C., S.T. and C.B. conducted chemical syntheses. R.A.S. and J.P. carried out the cell culture, experiments with cell lines, western blot experiments, microscopy and imaging. R.A.S. and M.B. performed statistical analyses. A.T.J.V., C.B., S.T., A.C. and J.M. provided material and resources. R.A.S., J.P., M.B., A.M. and F.M. interpreted the analyzed data. R.A.S. wrote the manuscript. A.M., M.B., F.M. and J.M. corrected the manuscript. All authors have read and agreed to the published version of the manuscript.
Affiliation 5: Department of Gynecology and Obstetrics, University Hospital Aachen, RWTH Aachen University, 52074 Aachen, Germany.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. Sankaranarayanan, R.A.; Peil, J.; Vogg, A.T.J.; Bolm, C.; Terhorst, S.; Classen, A.; Bauwens, M.; Maurer, J.; Mottaghy, F.; Morgenroth, A. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sankaranarayanan, R.A.; Peil, J.; Vogg, A.T.J.; Bolm, C.; Terhorst, S.; Classen, A.; Bauwens, M.; Maurer, J.; Mottaghy, F.; Morgenroth, A. Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230. Cancers 2023, 15, 2641. https://doi.org/10.3390/cancers15092641

AMA Style

Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A. Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230. Cancers. 2023; 15(9):2641. https://doi.org/10.3390/cancers15092641

Chicago/Turabian Style

Sankaranarayanan, Ramya Ambur, Jennifer Peil, Andreas T. J. Vogg, Carsten Bolm, Steven Terhorst, Arno Classen, Matthias Bauwens, Jochen Maurer, Felix Mottaghy, and Agnieszka Morgenroth. 2023. "Correction: Sankaranarayanan et al. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers 2022, 14, 230" Cancers 15, no. 9: 2641. https://doi.org/10.3390/cancers15092641

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop